We found that correlated variables reflecting tumor biomarkers (CA125, CEA, CA15-3), clinicopathological features (tumor diameter, N stage, molecular subtype), and coagulation abnormalities (Fbg, FVIII, D-dimer) have important weights in predicting the recurrence of BC. This evidence concerns the gene MUC16 and breast cancer.